Abstract
The Wilms tumor 1 (WT1) gene encodes a transcription factor that was among the first tumor suppressor genes to be identified. Dependent on the splice variant, some WT1 isoforms can function as transcriptional regulators, whereas other WT1 proteins are presumably involved in RNA processing. The mechanisms by which WT1 regulates transcription and the identification of bona fide target genes have been difficult to study, which is partially due to the complex nature of the gene and its context specific functions. While the role of WT1 as a tumor suppressor in Wilms tumor is widely accepted, considerable evidence points to an oncogenic function in other tumors. Recent studies have provided new insights into the underlying mechanisms that lead to the development of Wilms tumor. In addition, a conditional Wt1 knockout mouse model and RNAi-mediated screening approaches have uncovered new functions for WT1 in development and tumorigenesis.
Keywords: Apoptosis, HTRA2, Igf2, oncogene, senescence, WT1, sumoylation, phosporylation, Tumorigenesis, epithelial-mesenchymal
Current Pediatric Reviews
Title: Opposing Functions for the Wilms Tumor Protein 1 (WT1) in Tumorigenesis
Volume: 7 Issue: 4
Author(s): Jorg Hartkamp
Affiliation:
Keywords: Apoptosis, HTRA2, Igf2, oncogene, senescence, WT1, sumoylation, phosporylation, Tumorigenesis, epithelial-mesenchymal
Abstract: The Wilms tumor 1 (WT1) gene encodes a transcription factor that was among the first tumor suppressor genes to be identified. Dependent on the splice variant, some WT1 isoforms can function as transcriptional regulators, whereas other WT1 proteins are presumably involved in RNA processing. The mechanisms by which WT1 regulates transcription and the identification of bona fide target genes have been difficult to study, which is partially due to the complex nature of the gene and its context specific functions. While the role of WT1 as a tumor suppressor in Wilms tumor is widely accepted, considerable evidence points to an oncogenic function in other tumors. Recent studies have provided new insights into the underlying mechanisms that lead to the development of Wilms tumor. In addition, a conditional Wt1 knockout mouse model and RNAi-mediated screening approaches have uncovered new functions for WT1 in development and tumorigenesis.
Export Options
About this article
Cite this article as:
Hartkamp Jorg, Opposing Functions for the Wilms Tumor Protein 1 (WT1) in Tumorigenesis, Current Pediatric Reviews 2011; 7(4) . https://dx.doi.org/10.2174/157339611796892373
DOI https://dx.doi.org/10.2174/157339611796892373 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Meridianins: Marine-Derived Potent Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry p53: An Attractive Therapeutic Target for Cancer
Current Medicinal Chemistry Occurrence and Biological Activities of Eremophilane-type Sesquiterpenes
Mini-Reviews in Medicinal Chemistry Application of Charge Transfer Reactions for the Quantitative Spectrophotometric Determination of Cyclophosphamide in Pure and Pharmaceutical Formulation
Current Pharmaceutical Analysis Potential and Cytotoxicity of cis-Platinum Complex with Anti-tumor Activity in Combination Therapy
Recent Patents on Anti-Cancer Drug Discovery Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs
Current Pharmaceutical Biotechnology SDH Genes: From Glomic Tumours to Pheochromocytomas
Current Hypertension Reviews Stopping Cancer in its Tracks: Using Small Molecular Inhibitors to Target Glioblastoma Migrating Cells
Current Drug Discovery Technologies Multimodality Imaging of RNA Interference
Current Medicinal Chemistry Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Novel Insights Into c-Src
Current Pharmaceutical Design Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies
Current Neuropharmacology Supramolecular Approaches for Drug Development
Current Medicinal Chemistry Pregnancy, Programming and Preeclampsia: Gap Junctions at the Nexus of Pregnancy-induced Adaptation of Endothelial Function and Endothelial Adaptive Failure in PE
Current Vascular Pharmacology From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Trafficking of HIV-1 RNA: Recent Progress Involving Host Cell RNABinding Proteins
Current Genomics Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology The Signal Pathway of Antibiotic Alternatives on Intestinal Microbiota and Immune Function
Current Protein & Peptide Science